Journal
EMBO MOLECULAR MEDICINE
Volume 4, Issue 8, Pages 761-775Publisher
WILEY
DOI: 10.1002/emmm.201200244
Keywords
lung metastasis; sphingolipids; sphingomab; sphingosine kinase 1; sphingosine 1-phosphate
Categories
Funding
- National Institutes of Health [CA088932, DE016572, CA097165]
- Biogen/IDEC, Inc. (San Diego, CA)
- CTSA/SCTR (MUSC)
- NIH [C06 RR015455, P30 CA138313]
Ask authors/readers for more resources
Mechanisms by which cancer cells communicate with the host organism to regulate lung colonization/metastasis are unclear. We show that this communication occurs via sphingosine 1-phosphate (S1P) generated systemically by sphingosine kinase 1 (SK1), rather than via tumour-derived S1P. Modulation of systemic, but not tumour SK1, prevented S1P elevation, and inhibited TRAMP-induced prostate cancer growth in TRAMP+/+SK1-/- mice, or lung metastasis of multiple cancer cells in SK1-/- animals. Genetic loss of SK1 activated a master metastasis suppressor, Brms1 (breast carcinoma metastasis suppressor 1), via modulation of S1P receptor 2 (S1PR2) in cancer cells. Alterations of S1PR2 using pharmacologic and genetic tools enhanced Brms1. Moreover, Brms1 in S1PR2-/- MEFs was modulated by serum S1P alterations. Accordingly, ectopic Brms1 in MB49 bladder cancer cells suppressed lung metastasis, and stable knockdown of Brms1 prevented this process. Importantly, inhibition of systemic S1P signalling using a novel anti-S1P monoclonal antibody (mAb), Sphingomab, attenuated lung metastasis, which was prevented by Brms1 knockdown in MB49 cells. Thus, these data suggest that systemic SK1/S1P regulates metastatic potential via regulation of tumour S1PR2/Brms1 axis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available